Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 23;17(6):688.
doi: 10.3390/pharmaceutics17060688.

Nanoparticles for Glioblastoma Treatment

Affiliations
Review

Nanoparticles for Glioblastoma Treatment

Dorota Bartusik-Aebisher et al. Pharmaceutics. .

Abstract

GBM is the most common and aggressive primary brain tumor in adults, characterized by low survival rates, high recurrence, and resistance to conventional therapies. Traditional diagnostic and therapeutic methods remain limited due to the difficulty in permeating the blood-brain barrier (BBB), diffuse tumor cell infiltration, and tumor heterogeneity. In recent years, nano-based technologies have emerged as innovative approaches for the detection and treatment of GBM. A wide variety of nanocarriers, including dendrimers, liposomes, metallic nanoparticles, carbon nanotubes, carbon dots, extracellular vesicles, and many more demonstrate the ability to cross the BBB, precisely deliver therapeutic agents, and enhance the effects of radiotherapy and immunotherapy. Surface functionalization, peptide modification, and cell membrane coating improve the targeting capabilities of nanostructures toward GBM cells and enable the exploitation of their photothermal, magnetic, and optical properties. Furthermore, the development of miRNA nanosponge systems offers the simultaneous inhibition of multiple tumor growth mechanisms and the modulation of the immunosuppressive tumor microenvironment. This article presents current advancements in nanotechnology for GBM, with a particular focus on the characteristics and advantages of specific groups of nanoparticles, including their role in radiosensitization.

Keywords: glioblastoma; nanoparticles; radiosensitization; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
General division of the nanoparticle groups discussed in this review.
Figure 2
Figure 2
Scheme of the action of nanoparticles to increase the radiosensitivity of GBM.

Similar articles

References

    1. Pouyan A., Ghorbanlo M., Eslami M., Jahanshahi M., Ziaei E., Salami A., Mokhtari K., Shahpasand K., Farahani N., Meybodi T.E., et al. Glioblastoma multiforme: Insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol. Cancer. 2025;24:58. doi: 10.1186/s12943-025-02267-0. - DOI - PMC - PubMed
    1. Wen P.Y., Weller M., Lee E.Q., Alexander B.M., Barnholtz-Sloan J.S., Barthel F.P., Batchelor T.T., Bindra R.S., Chang S.M., Chiocca E.A., et al. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology. 2020;22:1073–1113. doi: 10.1093/neuonc/noaa106. - DOI - PMC - PubMed
    1. Lerner A., Palmer K., Campion T., O Millner T., Scott E., Lorimer C., Paraskevopoulos D., McKenna G., Marino S., Lewis R., et al. Gliomas in adults: Guidance on investigations, diagnosis, treatment and surveillance. Clin. Med. 2024;24:100240. doi: 10.1016/j.clinme.2024.100240. - DOI - PMC - PubMed
    1. Roda D., Veiga P., Melo J.B., Carreira I.M., Ribeiro I.P. Principles in the Management of Glioblastoma. Genes. 2024;15:501. doi: 10.3390/genes15040501. - DOI - PMC - PubMed
    1. Schaff L.R., Mellinghoff I.K. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023;329:574–587. doi: 10.1001/jama.2023.0023. - DOI - PMC - PubMed

LinkOut - more resources